Lexicon Pharmaceuticals (LXRX) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
5 Nov, 2026Executive summary
SONATA-HCM enrollment completed with 542 patients; topline results and a planned ZYNQUISTA NDA resubmission are both expected in Q1 2027.
Q3 revenue was $11.3M, including a third $10M Novo Nordisk milestone; 2026 milestone receipts totaled $30M as of Nov. 5.
Portfolio priorities include sotagliflozin for HCM and T1D, LX9851 in Novo Nordisk Phase 1 development, and pilavapadin for neuropathic pain and other indications.
Financial highlights
Q3 revenue was $11.3M vs. $14.2M in Q3 2025; 2026 revenue included a $10M Novo milestone and $1.2M in INPEFA net sales.
R&D expense was $16.2M vs. $18.8M, SG&A was $9.5M vs. $7.6M, and total operating expenses were $25.7M vs. $26.4M.
Net loss was $14.0M, or $0.03/share, vs. $12.8M, or $0.04/share; each period included $3.4M of non-cash stock-based compensation.
Nine-month revenue was $33.0M vs. $44.3M; net loss was $46.8M vs. $34.8M, and operating expenses were $75.1M vs. $78.4M.
Outlook and guidance
FY 2026 operating expense guidance remains $100M–$110M: R&D $63M–$68M and SG&A $37M–$42M; guidance excludes Phase 3 pilavapadin trial expenses.
SONATA-HCM topline results and ZYNQUISTA NDA resubmission are expected in Q1 2027; SOTA-CROSS nHCM study completion is expected in 1H 2027.
Current unrestricted cash and investment balances, plus expected collaboration and other revenue, are projected to fund planned operations for at least 12 months from the report date.
Further pilavapadin development depends on strategic collaboration or other financing; existing capital is insufficient for Phase 3 DPNP or broader neuropathic pain development.
Latest events from Lexicon Pharmaceuticals
- SONATA’s Q1 2027 readout and type 1 diabetes resubmission anchor near-term catalysts.LXRX
Jefferies Global Healthcare Conference - Late-stage pipeline advances and key trial readouts set up major milestones by early 2027.LXRX
H.C. Wainwright 28th Annual Global Investment Conference - Phase III HCM data for sotagliflozin expected Q1, with strong pipeline and regulatory momentum.LXRX
12th Annual Cantor Fitzgerald Global Healthcare Conference - SONATA-HCM phase III data expected Q1 2027, with T1D resubmission and pipeline advances underway.LXRX
Citigroup’s Biopharma Back to School Summit 2026 - Shares registered for resale by warrant holders; no proceeds to company; focus on heart failure drugs.LXRX
Registration filing - Q2 2026 net loss was $31.8M; SONATA-HCM Phase 3 enrollment completed, NDA resubmission Q4 2026.LXRX
Q2 2026 - Major clinical and partnership milestones achieved, with pivotal data and regulatory catalysts ahead.LXRX
Evercore ISI 8th Annual HealthCONx Conference - Multiple late-stage programs approach pivotal milestones, with regulatory and clinical catalysts ahead.LXRX
Jefferies London Healthcare Conference 2024 - LX9211 and pilavapadin advance as non-opioid therapies with imminent phase IIb data in DPNP.LXRX
R&D Day 2025